Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:

NCT ID: NCT06387017 Recruiting - Lung Cancer Clinical Trials

Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway

BIOCEPTION
Start date: April 2, 2024
Phase: N/A
Study type: Interventional

Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.

NCT ID: NCT06386653 Enrolling by invitation - Lung Cancer Clinical Trials

Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1

Start date: May 14, 2024
Phase: Phase 1
Study type: Interventional

The study should evaluate the biological distribution of [123I]I-DARPIN-Ec1 in patients with lung and ovarian cancer The primary objective are: 1. To assess the distribution of [123I]I-DARPIN-Ec1 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of [123I]I-DARPIN-Ec1 . 3. To study the safety and tolerability of the drug [123I]I-DARPIN-Ec1 after a single injection in a diagnostic dosage. The secondary objective are: 1. To compare the obtained [123I]I-DARPIN-Ec1 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in lung and ovarian cancer patients.

NCT ID: NCT06384417 Not yet recruiting - Breast Cancer Clinical Trials

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

Start date: June 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with various solid cancer types (including: breast, gastro-intestinal, lung, melanoma, head and neck, and/or genito-urinary cancers) treated at Penn State Health clinics and their loved ones perform advance care planning (ACP). The main questions it aims to answer are: What modifications and/or adaptations are necessary to Hello for use in cancer populations? What impact does participation in Hello event have on health care usage (e.g., number of hospitalizations, ICU admissions, emergency department visits, etc.)? How feasible is it to randomize participants to play either Hello for Cancer or Table Topics? Participants will: - Complete pre-game questionnaires - Play either Hello or Table Topics game - Complete post-game questionnaires - Participate in a focus group - Complete a telephone follow up interview 1-4 months after their event This study is a continuation of NCT06028152.

NCT ID: NCT06383728 Recruiting - Lung Cancer Clinical Trials

Osimertinib as Neoadjuvant Therapy in Patients With Resectable Stage II-IIIB EGFR-mutated Lung Squamous Cell Carcinoma

GALAXY-02
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

Previous trials, such as ADURA and CTONG, have demonstrated the benefits of neoadjuvant targeted therapy in patient with EGFR mutations , which can effectively reduce the extent of tumors and improve the survival outcomes. However, clinical trials of neoadjuvant targeted therapy in NSCLC have rarely enrolled patients with EGFR-mutated lung squamous cell carcinoma due to its rarity, which means that the safety and feasibility of neoadjuvant osimertinib in patients with resectable stage II-IIIB EGFR-mutated lung squamous cell carcinoma remains relatively unknown.

NCT ID: NCT06381960 Recruiting - Lung Cancer Clinical Trials

Clinical Study on the Prevention and Treatment of Postoperative Metastasis of Lung Cancer by Fuzheng Quxie Recipe

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

To address the clinical challenge of postoperative metastasis in stage IIA-IIIA non-small cell lung cancer with negative driver gene expression, there is a lack of effective diagnostic and therapeutic measures. Based on this, investigators propose to carry out a clinical study on the prevention and treatment of postoperative metastasis of IIA-IIIA stage lung cancer with negative driver gene expression with the formula of supporting the positive and dispelling the evil.

NCT ID: NCT06380361 Not yet recruiting - Lung Cancer Clinical Trials

InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology

INSPECT
Start date: April 20, 2024
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.

NCT ID: NCT06377124 Not yet recruiting - Lung Cancer Clinical Trials

A Smart Self-Management Support Programme (3S) to Improve Quality of Life in Lung Cancer Patients

Start date: April 22, 2024
Phase: N/A
Study type: Interventional

Lung cancers patients often experience multiple symptoms (e.g. fatigue, dyspnea, distress, depression, sleep disturbance). The current study attempts to explore the efficacy of the Smart Self-Management Support Programme (3S) in improving quality of life of patients using self-management support programme with mobile devices.

NCT ID: NCT06376253 Not yet recruiting - Lung Cancer Clinical Trials

A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers

Start date: September 6, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-EVS459 and the safety and imaging properties of [68Ga]Ga-EVS459 in patients aged ≥ 18 years with advanced high-grade serous ovarian cancer (OC) or locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (non-sq. NSCLC).

NCT ID: NCT06376097 Recruiting - Lung Cancer Clinical Trials

Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.

Start date: April 19, 2023
Phase:
Study type: Observational

Observational study that aims to evaluate the implementation of a lung cancer screening program in a smoker population included in a public heath service.

NCT ID: NCT06375187 Not yet recruiting - Breast Cancer Clinical Trials

Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors

KUNLUN-001
Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors